Physical Address

304 North Cardinal St.
Dorchester Center, MA 02124

Lilly’s weight loss pill orforglipron could get FDA approval in 2026, CEO Dave Ricks says.


Eli Lilly & Co., the Fortune 500 pharma firm that makes the weight-loss vaccine Zepbound (tirzepatide), has a similar oral drug in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks said. told Bloomberg TV on Jan. 13, 2025.

Eli Lilly & Co., the Fortune 500 pharma firm that makes the weight-loss vaccine Zepbound (tirzepatide), has a similar oral drug in the works that could be approved by the FDA as early as 2026, CEO Dave Ricks said. told Bloomberg TV on Jan. 13, 2025.

Gam1983/Getty Images



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *